STOCK TITAN
  1. Home
  2. News
  3. GERN

Geron Announces September Investor Conference Presentation Webcasts

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Geron Corporation (Nasdaq: GERN) today announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, is scheduled to present at the following investor conferences:

  • H.C. Wainwright 23rd Annual Global Virtual Investment Conference on Monday, September 13, 2021 at 7:00 a.m. ET.
  • R.W. Baird 2021 Virtual Global Healthcare Conference on Tuesday, September 14, 2021 at 2:00 p.m. ET.
  • 2021 Cantor Virtual Global Healthcare Conference on Thursday, September 30, 2021 at 3:20 p.m. ET.

A live webcast of each presentation will be available through the Investor Relations section of Geron’s website under Events. Following the presentations, the webcasts will be archived and available for replay for a period of 30 days.

About Geron

Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The Company currently is conducting two Phase 3 clinical trials: IMerge in lower risk myelodysplastic syndromes and IMpactMF in refractory myelofibrosis. For more information about Geron, visit www.geron.com.

Olivia Bloom

Chief Financial Officer

investor@geron.com

media@geron.com

Source: Geron Corporation

Stock GERN logo
Geron Corp.

NASDAQ:GERN

GERN Rankings

#1788 Ranked by Market Cap
#3292 Ranked by Stock Gains
N/A Ranked by Dividends

GERN Latest News

Apr 18, 2024
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Apr 3, 2024
Geron to Participate at Upcoming Investor Conferences in April
Mar 19, 2024
Geron Corporation Announces Pricing of $150 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Mar 14, 2024
Geron Announces FDA Oncologic Drugs Advisory Committee Votes in Favor of the Clinical Benefit/Risk Profile of Imetelstat for the Treatment of Transfusion-Dependent Anemia in Patients with Lower-Risk MDS
Feb 28, 2024
Geron Corporation Reports Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

GERN Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Health Technology, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing
US
Foster City

About GERN

we are a biopharmaceutical company developing first-in-class therapies for cancer. imetelstat, a novel, first-in-class telomerase inhibitor, is our product candidate in clinical development. telomerase enables cancer cells to maintain telomere length, which provides them with the capacity for limitless cellular replication. imetelstat is a potent and specific inhibitor of telomerase. based on clinical data we obtained in late 2012, we may develop imetelstat to treat one or more hematologic myeloid malignancies such as myelofibrosis, or mf, myelodysplastic syndromes, or acute myelogenous leukemia.